A phosphoinositide kinase specific for the D-3 position of the inositol ring, phosphatidylinositol (PI) 3-kinase, associates with activated receptors for platelet-derived growth factor, insulin, and colony-stimulating factor 1, with products of the oncogenes src, fins, yes, crk, and with polyomavirus middle T antigen. Efficient fibroblast transformation by proteins of the abi and src oncogene families requires activation of their protein-tyrosine kinase activity and membrane association via an amino-terminal myristoylation. We have demonstrated that the PI 3-kinase directly associates with autophosphorylated, activated protein-tyrosine kinase variants of the abl protein. In vivo, this association leads to accumulation of the highly phosphorylated products of PI 3-kinase, PI-3,4-bisphosphate and PI-3,4,5-trisphosphate, only in myristoylated, transforming abl protein variants. Myristoylation thus appears to be required to recruit PI 3-kinase activity to the plasma membrane for in vivo activation and correlates with the mitogenicity of the abl protein variants.
The protein-tyrosine kinase activities of several growth factor receptors and oncogene products have been implicated in mitogenesis and transformation. Kinase-inactive mutants of the platelet-derived growth factor (PDGF) receptor and other protein-tyrosine kinase-containing receptors fail to stimulate cell division in response to their respective ligands (5, 6, 10, 14, 15) , and kinase-defective v-abl, v-fps, and v-src oncogene mutants do not transform cells, suggesting that protein-tyrosine phosphorylation regulates critical events in the control of cell proliferation (2, 32, 35, 42) . Whereas the growth factor receptors are transmembrane proteins with ligand-binding properties, cellular proteins of the abl and src oncogene families associate with the inner surface of the plasma membrane via amino-terminal myristoylation. src and abl protein mutants which cannot be myristoylated no longer associate with the plasma membrane and are defective in cell transformation (7, 13, 25, 33) . These observations suggest either that the critical substrates of the tyrosine kinases are at the plasma membrane or that the substrates must be recruited to the plasma membrane following activation of the protein-tyrosine kinases.
Several enzymes that participate in signal transduction in association with protein-tyrosine kinases have recently been described. Phosphatidylinositol (PI)-specific phospholipase C gamma is phosphorylated on tyrosine and associates with the PDGF and epidermal growth factor receptors following ligand binding (20, 24, 27, 41) . Activation of phospholipase C is temporally linked to activation of several growth factor receptors and with cell transformation induced by oncogenes. ras-GAP (ras GTPase-activating protein) and the proto-oncogene c-raf also form a complex with the PDGF receptor following ligand binding (21, 29, 30, 31) . A phosphoinositide kinase that phosphorylates the D-3 position of the inositol ring (PI 3-kinase), associates with the receptors for PDGF, insulin, epidermal growth factor, and colonystimulating factor 1 (CSF-1), with products of the oncogenes * Corresponding author. src, fms, yes, crk, and with polyomavirus middle T antigen (mT) (11, 12, 19, 34, 38, 40, 44) . PI 3-kinase has been purified to homogeneity from rat liver and contains 110-and 85-kDa subunits (4). The 85-kDa subunit of PI 3-kinase is found in a complex with the PDGF-R and mT/pp6Ocsrc and is phosphorylated on serine and tyrosine residues (19) . Elevated levels of PI 3-kinase products are found in cells stimulated with growth factors and in transformed cells (1, 36, 40) . The role that these phospholipids play in mitogenesis in unknown, but they may act as a novel second messenger system.
We investigated whether PI 3-kinase is activated by normal and transforming abl proteins. The v-abl protein transforms NIH 3T3 fibroblasts, whereas the BCRIabl fusion protein associated with chronic myelogenous leukemia transforms pre-B lymphocytes but not NIH 3T3 fibroblasts (8, 9, 26, 33) . A variant of the BCR/abl protein which carries the retrovirus gag protein sequence at its N terminus (gag! BCR/abl protein) efficiently transforms NIH 3T3 fibroblasts and resembles the v-abl protein in its leukemogenic properties in vivo (9) . The gagIBCR/abl protein associates in part with the plasma membrane (7a.), presumably through the myristoylated N terminus. Naturally occurring c-abl protein types are weak protein-tyrosine kinases and do not transform fibroblasts even when expressed at very high levels, whether or not they are myristoylated (16, 39) . Structural deletions at the c-abl protein N terminus result in activation of protein-tyrosine kinase activity, phosphorylation of the abl proteins on Tyr residues in vivo, and transformation (16) . In the present study, we report that certain cellular products of generated by cotransfection of a construct encoding the 160-kDa gaglv-abl protein (v-abl protein) with Moloney helper virus. The generation of transformed cell lines expressing gagIBCRIabl, the c-abl mutant AX B, and the nontransformed cell lines expressing high levels of c-abl type IV and p210 (BCR/abI) proteins has been described previously (9, 16) .
The cell line expressing the gagIBCRIabl (gag p210) fusion protein carries a cloned facsimile of the spontaneously arising p220 gagIBCRIabl protein which was made by fusing retrovirus gag sequences derived from v-abl to a BCR sequence by using the 5' HincIl site in v-abl and the HinclI site at position 1194 in the BCR sequence (9, 28) . This gene encodes a gagIBCRIabl protein of 210 kDa, with the first 240 amino acid residues of the gag protein replacing the first 241 residues of BCR. When expressed in a retrovirus construct, this protein readily transforms NIH 3T3 fibroblasts. The Ax B-K290M mutant was made by oligonucleotide-directed mutagenesis of the lysine at position 290 of the tyrosine kinase domain (16a). This residue, which is involved in ATP binding (18) , was mutated to methionine. Constructs specifying the Ax B-K290M mutant were cotransfected at a high molar ratio (10:1) with a plasmid carrying the neo gene, which determines resistance to the antibiotic G418. After selection ofG418-resistant clones, the clones were screened for high levels of protein expression. The expressed protein is defective in protein-tyrosine kinase function and is unable to transform fibroblasts (16a).
Cell lines were considered transformed on the basis of the following criteria: round and refractile morphology, growth to high density, and ability to form colonies after suspension in semisolid agar medium. Both transformed and nontransformed NIH 3T3 cells expressed abl protein variants at high levels relative to endogenous c-abl protein.
Association of PI 3-kinase activity with abl oncoproteins in vitro. Immunoprecipitable PI 3-kinase was obtained by using monoclonal antibody directed against either phosphotyrosine (anti-P-Tyr antibody was a gift of Brian Drucker) or C-terminal abl protein determinants (monoclonal antibody 2421 was a gift of Naomi Rosenberg). NIH 3T3 cells expressing mutant abl proteins were grown in DMEM-10% calf serum to confluence for nontransformed cells and to high density for transformed cells. Cells were deprived of serum for 2 to 3 doubling times (36 to 48 h). Cells were lysed in buffer containing 1% Nonidet P-40 as described previously (44) . Lysates were incubated with the appropriate antibody for 3 h and collected on protein A-Sepharose beads (Sigma). The beads were washed extensively with lysis buffer, phosphate-buffered saline (PBS), 0.5 M LiCl, and TNE buffers as described previously (44) . Immunoprecipitable PI kinase activity was assayed in 25 mM HEPES (N-2-hydroxyeth-
MgCl2 in the presence of a 0.2-mg/ml mixture of specific phospholipids with phosphatidylserine as a carrier (the lipids were dried under nitrogen and sonicated for 10 min in 25 mM HEPES [pH 7.8]-1 mM EDTA prior to addition). The reaction was initiated by the addition of 100 ,uM ATP and 20 ,uCi of [_y-32P]ATP and stopped after 5 min with an equivalent volume of 0.1 M HCl. The lipids were extracted into methanol-chloroform as described previously (44) . A fraction of extracted lipids was separated by thin-layer chromatography in chloroform-methanol-H20-concentrated NH40H (60:47:11.3:2) and visualized by autoradiography. The remaining phospholipids were subjected to deacylation and fractionated by high-performance liquid chromatography (HPLC) (1, 40) . In several experiments, cells were exposed to 10 nmol of PDGF-BB per ml for 10 min prior to lysis to measure cell viability and activation of endogenous PI 3-kinase.
Identification of PI 3-kinase products in vitro and in vivo. A fraction of phospholipids generated in the in vitro PI kinase assay was deacylated in methylamine as described previously (1), suspended in 400 1.l of H20 with appropriate 3H standards, and separated by HPLC on a Partisphere SAX column with an (NH4)2HP04 gradient (0 to 1 M) (40) . For in vivo labeling and phospholipid identification, cells were grown to confluence (nontransformed) or high density (transformed) and deprived of serum for 48 h as described above.
The cells were labeled with 32p; (0.1 mCi/ml) in phosphatefree minimal essential medium (MEM) for 3 h prior to lysis. Cells were washed with iced MEM and scraped into 0. 1B) . In nontransfected control cells and cells overexpressing the c-abl type IV protein, anti-P-Tyr-immunoprecipitable PI kinase activity was detected only following stimulation with PDGF-BB (Fig. 1A, lanes 2 and 4) . However, fibroblasts expressing BCRIabl protein were not transformed but still had immunoprecipitable PI 3-kinase activity. This activity was detected by using anti-P-Tyr or anti-abl protein antibodies (Fig. 1B, lanes 6 and 9) . The anti-P-Tyr-immunoprecipitable PI 3-kinase activity increased further to levels comparable to those detected in control NIH 3T3 cells in response to PDGF-BB (Fig. 1B, lanes 6 and 7) . A phosphoprotein which comigrated with an 85-kDa phosphoprotein from PDGF-stimulated NIH 3T3 fibroblasts and cells expressing the kinase-inactive K290M mutant protein was phosphorylated in anti-abl protein immunoprecipitates from cells transformed by the AxB mutant protein (Fig. 2) . Similar protein results were obtained with cells expressing gag/BCRIabl proteins (data not shown).
Identification of the product of immunoprecipitable PI kinase. The products of the lipid kinase activity detected in the anti-abl protein immunoprecipitates were deacylated and identified by HPLC. Under the conditions of the assay (i.e., absence of detergents [43] ), most of the newly formed phospholipid was PI-3-P (Fig. 3) . Similar results were obtained when anti-P-Tyr antibodies were used (data not shown). These 2) and cells over expressing c-abl type IV protein (lanes 3 and 4). Cells were grown to confluency in 100-mm plates and brought to quiescence in DMEM supplemented with 1% bovine serum albumin for the last 48 h of culture. A duplicate plate of each cell line was exposed to 10 ng of PDGF-BB per ml for 10 min (lanes 2 and 4). Cells were lysed in a buffer containing 1% Nonidet P-40, and PI kinase was immunoprecipitated by using monoclonal anti-PTyr antibody and protein A-Sepharose beads. PI (0.1 mg/ml) was used as the substrate with 0.1 mg of phosphatidylserine per ml as a carrier with 100 ,uM ATP and 20 p.Ci of [y-32P]ATP. The reaction was terminated by addition of 1 N HCI, and the phospholipids were extracted into chloroform-methanol (2:1), dried under N2, separated by thin-layer chromatography as described in Materials and Methods, and visualized by autoradiography. The migration position of the newly formed PIP was detected by using nonradioactive PIP which was run in parallel with the samples and visualized by exposure to iodine vapors. (B) PIP formed in immunoprecipitates from whole-cell lysates obtained from control NIH 3T3 cells (lanes 1 and 12) and cells expressing v-abl (lanes 2 and 11), gagIBCR/abl (lanes 3 and 10), AxB (lanes 4, 5, and 8), and BCR/abl (lanes 6, 7, and 9) proteins. In lanes 5 and 7 cells were exposed to PDGF-BB for 10 min prior to harvest. PI kinase activity was assayed in the immunoprecipitates obtained by using monoclonal anti-P-Tyr (lanes 1 to 7) or monoclonal anti-abl protein (lanes 8 to 12) antibodies. The lipid kinase reaction was performed as described above. The products were separated by thin-layer chromatography and visualized by autoradiography.
ally below the detection limit (as judged by incorporation of [3H]inositol; <0.5% of PI-4-P [36] ). Detectable incorporation of [3H]inositol or 32p; into PI-3,4-P2 and PIP3 appeared upon stimulation with PDGF, CSF-1, and insulin (1, 34, 40) . Levels of the same lipids are elevated in cells transformed by polyomavirus mT (36) . If expression of transforming abl proteins activates PI 3-kinase, the steady-state levels of PI 3-kinase products should be at least transiently elevated. Fibroblasts expressing abl protein variants were deprived of serum and labeled with 32P043-. Total lipids were extracted, deacylated, and analyzed by HPLC as described above. Fibroblasts transformed by v-abl, AxB, and gagIBCR/abl proteins had detectable levels of PI-3,4-P2 and PIP3. phospholipids in the transformed cell lines was similar to that found in PDGF-stimulated smooth muscle cells, CSF-1-stimulated fibroblasts which express the human CSF-1 receptor, and polyomavirus-transformed fibroblasts (1, 36, 40) . Very low incorporation of 32p (<0.5% of the total) was detected in PI-3,4-P2 or PIP3 in control NIH 3T3 cells (Fig.  4B and C and Fig. 5 ) or in nontransformed cells expressing high levels of the normal c-abl type IV protein or Ax B kinase-deficient mutant protein (Ax B-K290M) (data not shown). Quiescent cells expressing nontransforming BCR/ abl protein had low but detectable incorporation of 32p into PI-3,4-P2, at about one-half of that found in transformed cells, and no detectable label in PIP3 (Fig. 4B and C In addition to an activated protein-tyrosine kinase, the abl protein appears to need amino (N)-terminal myristoylation for efficient transformation of fibroblasts. The v-abl oncogene product and AxB mutant protein have the myristoylation sequence and efficiently transform cells. The BCRIabl protein lacks the myristoylation sequence and fails to transform NIH 3T3 cells, although it does confer growth factor independency for some lymphocyte cell lines (8, 26) and weakly transforms Rat-1 cells (23) . Attachment of the retrovirus gag protein sequence to the N terminus of the BCR/abl protein provides a myristoylation sequence and makes this gene product strongly transforming for NIH 3T3 fibroblasts (9) . The importance of amino-terminal myristoylation is also supported by results obtained with v-abl and AxB gene products which lack the myristoylation sequence and fail to transform fibroblasts (16a) .
The characteristics of the abl protein variants which were studied are summarized in Fig. 6 . Mutants in which the abl protein failed to activate PI 3-kinase had decreased levels of PI-3,4-P2 and extremely low levels of PIP3 and were transformation defective. The BCR/abl protein has high proteintyrosine kinase activity and associates with PI 3-kinase but is not transforming. Significantly, cells transfected with the BCRIabl gene did not have detectable PIP3. These results suggest that mere association of the PI 3-kinase with an activated protein-tyrosine kinase is insufficient to increase the level of products of the enzyme in intact cells. The implication is that amino-terminal myristoylation is also needed to place the abl protein/PI 3-kinase complex at a membrane location where lipid phosphorylation can occur efficiently. Thus, transformation by the abl oncogene product correlates better with the cellular levels of PIP3 than with abl-associated PI 3-kinase activity. An analogous pp60-src mutant protein, which lacks the amino-terminal myristoylation sequence, was also found to associate with PI 3-kinase (11) but not to transform fibroblasts (17) . However, the levels of PI-3,4-P2 and PIP3 in vivo were not investigated. The present results predict that PIP3 would not be present under quiescent conditions in those cells.
The role of D-3-phosphorylated polyphosphoinositides in signal transduction is unclear. The pathways for synthesizing and degrading these lipids are complicated and appear to be regulated at multiple steps by different growth factors and hormones (3) . As a consequence, the cellular ratios of PI-3-P to PI-3,4-P2 to PIP3 vary dramatically in response to growth factors, hormones, and transformation by oncogenes. Although PI-3,4-P2 and PIP3 can be produced by phosphorylation of PI-4-P and PI-4,5-P2, respectively, by a purified PI 3-kinase (4), an alternative pathway for PI-3,4-P2 synthesis exists, involving phosphorylation of PI-3-P at the D-4 position (45) . None of the D-3-phosphorylated lipids is a substrate for the PI-specific phospholipases C that have been investigated (22, 37) , indicating that the appearance of these lipids is controlled independently of the canonical PI turnover pathway. Thus far, the evidence that these lipids regulate growth is based on mutational studies of growth factor receptors and oncogenes. Further biochemical studies to determine their cellular targets are under way.
